Blue Earth Diagnostics Highlights Presentations on POSLUMA® (Flotufolastat F 18), Axumin® (Fluciclovine F 18) and Investigational 18F-Flotufolastat/18F-rhPSMA-7 at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting
Blue Earth Diagnostics invites participants at the 2024 SNMMI Annual Meeting to attend the presentations above and to visit the Company at Exhibit Booth 1639.
- Blue Earth Diagnostics invites participants at the 2024 SNMMI Annual Meeting to attend the presentations above and to visit the Company at Exhibit Booth 1639.
- The Company is hosting a Satellite Symposium, “Let’s Talk about POSLUMA®,” which will discuss the most recent innovations in PSMA-PET imaging for prostate cancer.
- Blue Earth Diagnostics also has a Medical Affairs information booth at SNMMI, where attendees can learn about the Company’s clinical research.
- A negative image does not rule out recurrent prostate cancer and a positive image does not confirm its presence.